Scientists have developed the “holy grail” diabetes treatments - a “smart” insulin that responds in real time to fluctuations in one’s blood sugar level.
The newly developed NNC2215 is effective as human insulin at lowering blood glucose in rats and pigs.
The engineered insulin requires a significant glucose spike to be activated, and once it is activated, there is a sudden rush of insulin in the system.
Type 1 diabetes, which often starts in childhood, occurs when the pancreas does not produce insulin (or enough insulin).
Type 2 diabetes sees the cells of the body develop resistance to insulin, meaning greater amounts are required that what is produced by the pancreas.